A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment WithdrawalGiuseppe Floris, Patrick Schöffski, Agnieszka Woźniak et al.|Clinical Cancer Research|2012Cited by 69
Supplementary Figure Legend from A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment WithdrawalGiuseppe Floris, Patrick Schöffski, Agnieszka Woźniak et al.|Unknown|2023Cited by 0
Supplementary Figure 2 from A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment WithdrawalGiuseppe Floris, Patrick Schöffski, Agnieszka Woźniak et al.|Unknown|2023Cited by 0
Data from A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment WithdrawalGiuseppe Floris, Patrick Schöffski, Agnieszka Woźniak et al.|Unknown|2023Cited by 0
Supplementary Table 2 from A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment WithdrawalGiuseppe Floris, Patrick Schöffski, Agnieszka Woźniak et al.|Unknown|2023Cited by 0